Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 2, 2007, Pages 645-650

  Lefrançois, Sébastien ^a   Robert, Jérôme ^a   Chauffour, Aurélie ^a   Ji, Baohong ^a   Jarlier, Vincent ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; RIFAMPICIN; STREPTOMYCIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; BURULI ULCER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FOOT PAD; INFLAMMATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM ULCERANS; RIFAMPIN; STREPTOMYCIN; TREATMENT OUTCOME;

EID: 33846607261     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00821-06     Document Type: Article

References (12)

1. Bentoucha, A., J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 45:3109-3112.
2. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
3. Dega, H., A. Bentoucha, J. Robert, V. Jarlier, and J. Grosset. 2002. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 46:3193-3196.
4. Dega, H., J. Robert, P. Bonnafous, V. Jarlier, and J. Grosset. 2000. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 44:2367-2372.
5. Etuaful, S., B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, G. K. Amedofu, P. Awuah, E. Ampadu, G. Amofah, K. Asiedu, and M. Wansbrough-Jones. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 49:3182-3186.
6. Ji, B., S. Lefrancois, J. Robert, A. Chauffour, C. Truffot, and V. Jarlier. 2006. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobactenum ulcerans. Antimicrob. Agents Chemother. 50:1921-1926.
7. Peto, R., M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, S. V. Howard, N. Mantel, K. McPherson, J. Peto, and P. G. Smith. 1977. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer 35:1-39.
8. Shepard, C. C., and D. H. Mc Rae. 1968. A method for counting acid-fast bacteria. Int. J. Lepr. 36:78-82.
9. van der Werf, T. S., Y. Stienstra, R. C. Johnson, R. Phillips, O. Adjei, B. Fleischer, M. H. Wansbrough-Jones, P. D. Johnson, F. Portaels, W. T. van der Graaf, and K. Asiedu. 2005. Mycobacterium ulcerans disease. Bull. W. H. O. 83:785-791.
10. van der Werf, T. S., W. T. van der Graaf, J. W. Tappero, and K. Asiedu. 1999. Mycobacterium ulcerans infection. Lancet 354:1013-1018.
11. World Health Organization. 2004. Buruli ulcer disease. Wkly. Epidemiol. Rec. 79:193-200.
12. World Health Organization. 2004. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). WHO/CDS/CPE/GBUI/2004.10. World Health Organization, Geneva, Switzerland.